Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated
Use
This test is useful for determining the proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with breast carcinoma. By measuring the amount of tumor cells expressing Ki-67, an estimate of DNA synthesis can be determined. Ki-67 (MIB-1) analysis provides useful prognostic and predictive information in various tumor types.
Special Instructions
Not provided.
Limitations
The paraffin block analyzed must be representative of the patient's tumor. Test results should be interpreted in the context of clinical findings and other laboratory data. Cases that cannot be scanned for automated analysis will be changed to the manual process for analysis.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Ki-67 (MIB-1)
Antibody
LOINC Codes
- 85330-9 - Ki-67 nuclear Ag NFr Br ca spec ImStn
- 44638-5 - Histo type BT
- 21918-8 - Other staging classification Cancer
- 85330-9 - Ki-67 nuclear Ag NFr Br ca spec ImStn
- 19139-5 - Pathologist name
- 81178-6 - Block description and site Spec
- 62364-5 - Test performance info Spec
- 80398-1 - Unique ID Current sample
- 29593-1 - Ki-67 nuclear Ag NFr Tiss ImStn
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Pathology Packaging Kit
Collection Instructions
Submit paraffin-embedded invasive or metastatic breast carcinoma tissue. It's acceptable to provide 2 unstained sections on charged slides cut at 4 microns less than 1 month ago, fixed in 10% neutral buffered formalin. Also include one hematoxylin and eosin-stained slide if possible.
Storage Instructions
Ambient preferred. Refrigerated also acceptable.
Causes for Rejection
No specimen should be rejected.